Case Study: Leading Life Science Manufacturing Company achieves scalable, unified market access for rare disease therapies with IntegriChain

Achieving Operational Success for Rare Disease Therapies Using a Unified Platform

Leading Life Science Manufacturing Company, a decentralized organization funding disease‑specific “research pods” to develop rare‑disease therapies, struggled to scale Market Access operations and aggregate disparate channel, contract, pricing, and patient data. Faced with time‑consuming spreadsheet workflows, auditability concerns, and the need for timely, accurate KPIs, they engaged IntegriChain and its ICyte Platform (including Patient Access solutions) to centralize and standardize their data and processes.

IntegriChain deployed the ICyte Platform to master and refine channel and patient feeds (EDI, specialty pharmacy, distributor, hub and copay data), provide patient tokenization and guided analytics, and enable GTN scenario modeling and roll‑up reporting. The unified solution eliminated silos, improved data accuracy and auditability, delivered near‑real‑time KPIs (Time‑to‑Fill, Fill Rate, Time on Therapy, PDC), freed critical trade and market access resources from manual aggregation, and increased productivity and control across the parent and subsidiary organizations.